GRGUH2EM2202 - CME/CMLE - HER2 Breast Cancer Tweetorial 2: Examining the Implications of HER2-low

Course Description

HER2 Breast Cancer Tweetorial 2: Examining the Implications of HER2-low 

This 30-minute, CME/CMLE-accredited, Tweetorial was designed to help pathologists, laboratory professionals, and other members of the cancer care team gain an understanding of the clinical implications around HER2-low breast cancer and HER2 testing guidelines. This Tweetorial will cover the following topics: HER2-low breast cancer, HER2-low classification, the clinical implications of HER2-low for the cancer care team, and tools and resources for pathologists.

This Tweetorial was originally posted on ASCP's Twitter account (https://twitter.com/ASCP_Chicago), and a downloadable version can be found at ASCP's breast cancer resource page at https://bit.ly/her2low

The activity offers 0.5 CME/CMLE credit.

Faculty/Authors

Joseph Kim, MD, MPH, MBA
President, Q Synthesis LLC

Physician's Competency: Patient Care, Medical Knowledge, Practice-Based Learning, and Improvement

CME/CMLE Credit: 0.5
Estimated Completion Time: 0.5 hour
Format: Online educational activity

Credit Designation Statement

The American Society for Clinical Pathology (ASCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education (CME) for physicians.

The ASCP designates this enduring internet activity for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only credit commensurate with the extent of their participation in the activity.

ASCP designates this enduring internet activity for a maximum of 0.5 CMLE credit. This activity meets CMP and state re-licensure requirements for laboratory personnel.

For questions regarding CME credit, please contact ASCP Customer Service at 1-800-267-2727, during normal business hours: Monday through Friday, 8 a.m. to 6 p.m. Eastern Time

Method of Participation
To complete the activity and receive credit, the participant must complete the online activity. CME certificates will be provided online.

Commercial Support
Funded by independent educational grants from AstraZeneca Pharmaceuticals and Daiichi Sankyo, Inc.
Provided by the American Society for Clinical Pathology in partnership with Q-Synthesis, LLC

Instructions

To claim CME/CMLE credit for the exercise, do the following:

Review the Technical Considerations.
Click Go to Content and click the first module of the course.
Complete the Demographic Survey.
Review the Tweetorial Instructions
Review the Educational Activity.
Submit the course Evaluation.
Enter the maximum number of credits offered and click Claim CME/CMLE to register credit.

Faculty Disclosures

Technical Considerations

Release Dates: 11/2/2022
Review Date:
Expiration Date: 11/2/2025

Course Objectives

Upon completion of this activity, you will be able to:

Appropriately conduct IHC and ISH testing, classification, and reporting in routine and complex breast cancer cases across the HER2 spectrum in accordance with guidelines
Describe the science and emerging evidence around the diagnosis, testing, and treatment of patients with HER2-low breast cancer
Update laboratory processes and procedures
Outline ways to improve communication and coordination among pathologists, oncologists, and other members of the cancer care team when discussing HER2 test results in patients with breast cancer

Summary


Availability:	On-Demand


Credit Offered:	0.5 CME/CMLE Credit


Contains:	3 Courses